⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29662358 | 1.00 | — | — | |
| Bromide SCHEMBL20568119 | 0.98 | HSP90AA1 (0.37) | — | |
| Bromide SCHEMBL31661299 | 0.98 | HSP90AA1 (0.37) | — | |
| Bromide SCHEMBL23071143 | 0.96 | HSP90AA1 (0.36) | — | |
| SCHEMBL5582899 | 0.75 | — | — | |
| SCHEMBL29562566 | 0.75 | — | — | |
| SCHEMBL6711366 | 0.75 | — | — | |
| SCHEMBL2360937 | 0.75 | — | — | |
| SCHEMBL27663241 | 0.75 | — | — | |
| SCHEMBL15614439 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035367-A1 | PKC-Theta Modulators | CELGENE CORPORATION (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | C4 THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2025151517-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS ASSOCIATED WITH MISSFOLDING OF ALPHA-SYNUCLEIN PROTEIN | WAVEBREAK THERAPEUTICS LIMITED (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025125248-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS THAT OVEREXPRESS TSPAN1 | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (ES) | 2025-06-19 | — | — | WO | disclosed |
| US-20250163004-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2025-05-22 | — | — | US | disclosed |
| WO-2025103502-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250122179-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| EP-3010586-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014203217-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014203217-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-24 | — | — | WO | disclosed |
| US-8916593-B2 | Alkoxy-substituted 2-aminopyridines as ALK inhibitors | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2566858-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | Pfizer Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138751-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | PFIZER INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-4022897-A | 4H-PYRIDO(1,2-A) PYRIMIDIN-4-ONE DERIVATIVES | E. R. SQUIBB & SONS, INC. (US) | 1977-05-10 | — | — | US | disclosed |